Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Credo Technology Group Holding Ltd (CRDO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Credo Technology Group Holding Ltd — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.53 (market cap $39.89B), while Credo Technology Group Holding Ltd trades at $251.6 (market cap $48.07B). The key difference: Credo Technology Group Holding Ltd is the larger of the two by market cap, and Credo Technology Group Holding Ltd is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | CRDO | |
|---|---|---|
Market Cap | $39.89B | $48.07B |
Sector | Health | Technology |
52-Week High | $491.22 | $302.52 |
52-Week Low | $278.09 | $87.81 |
Enterprise Value | $38.15B | $46.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
CRDO trades at $257.79, down 2.96% today but maintains strong bullish momentum with analyst consensus at 'Buy' (86.7% of 15 analysts). The stock shows robust fundamentals with 35.37% net income margin and triple-digit revenue growth projections for 2026. Recent earnings consistently beat expectations, and technical indicators suggest bullish momentum with support at $258 and resistance at $276.
Outlook remains positive given AI infrastructure demand and strong financial performance, though elevated valuations (P/E 102.7) and customer concentration risks warrant caution. The consensus price target of $273.33 implies 6% upside potential from current levels, supported by institutional optimism and expanding market opportunities in high-speed connectivity solutions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Credo Technology Group Holding Ltd
Credo Technology provides high-speed connectivity solutions for AI-driven applications and hyperscale data centers. Its products enable faster, more energy-efficient data transmission for cloud and telecom infrastructure.
Read more on CRDO →
